Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The chat will feature Christopher Posner, CEO, Thomas Reilly, CFO, and Joana Goncalves, M.D., CMO. A webcast of the event will be available on the company’s website and archived for approximately 30 days.

Cara, focused on alleviating pruritus through kappa opioid receptors, received FDA approval for KORSUVA Injection on August 23, 2021, targeting chronic kidney disease-related pruritus.

STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Christopher Posner, President and Chief Executive Officer, Thomas Reilly, Chief Financial Officer, and Joana Goncalves, M.D., Chief Medical Officer, will participate in a fireside chat at the Piper Sandler 33^rd Annual Virtual Healthcare Conference. The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m. ET.

A webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com 

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com 

FAQ

What is the date and time of Cara Therapeutics' fireside chat at the Piper Sandler Conference?

The fireside chat is scheduled for November 22, 2021, at 10:00 a.m. ET.

Who are the participants in the fireside chat for Cara Therapeutics?

The participants include Christopher Posner, CEO, Thomas Reilly, CFO, and Joana Goncalves, M.D., CMO.

How can I access the webcast for Cara Therapeutics' fireside chat?

The webcast can be accessed under 'Events & Presentations' on Cara Therapeutics' website.

What recent FDA approval did Cara Therapeutics receive for KORSUVA?

KORSUVA Injection was approved by the FDA on August 23, 2021, for moderate-to-severe pruritus in chronic kidney disease patients.

What is the primary focus of Cara Therapeutics?

Cara Therapeutics focuses on developing treatments for pruritus by targeting peripheral kappa opioid receptors.